361 Capital’s Pacira BioSciences PCRX Stock Holding History

361 Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$981K	Sell	18,699 -2,903	-13%	-$121K	0.46%	44
2020 Q1	$724K	Buy	+21,602	New	+$897K	0.33%	138
2019 Q3	–	Sell	-57,402	Closed	-$2.5M	–	357
2019 Q2	$2.5M	Buy	+57,402	New	+$2.44M	0.44%	118
2019 Q1	–	Sell	-56,873	Closed	-$2.45M	–	383
2018 Q4	$2.45M	Buy	56,873 +9,703	+21%	+$453K	0.5%	50
2018 Q3	$2.32M	Buy	+47,170	New	+$2.04M	0.5%	22

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

361 Capital's PCRX Position: Q2 2020 in Review

361 Capital reduced its Pacira BioSciences (PCRX) stake by 13% in Q2 2020, selling an estimated $121K and leaving 18,699 shares worth $981K. The position accounts for 0.46% of the portfolio, ranked #44.

361 Capital first reported a position in PCRX in Q3 2018 and has held it in 5 quarters since. The position peaked at $2.5M in Q2 2019. 248 funds tracked by Wall St. Rank hold PCRX as of Q2 2020.

361 Capital held 18,699 shares of Pacira BioSciences worth $981K as of Q2 2020.
361 Capital sold 2,903 Pacira BioSciences shares in Q2 2020, an estimated $121K.
Pacira BioSciences made up 0.46% of 361 Capital's portfolio in Q2 2020, its #44 holding.
361 Capital first reported a position in Pacira BioSciences in Q3 2018 and has held it in 5 quarters since.
361 Capital's Pacira BioSciences position peaked at $2.5M in Q2 2019.
248 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.